What is it about?
This study examined whether curcumin can enhance the cytotoxic effects of the proteasome inhibitor carfilzomib (CFZ) in human multiple myeloma U266 cells. Curcumin significantly improved CFZ‑induced loss of viability, despite not inhibiting the proteasome at the tested concentration, indicating that the two compounds act through distinct mechanisms. Both curcumin and CFZ increased reactive species, activated the p53/p21 axis, and induced G0/G1 cell‑cycle arrest. Their combination produced stronger effects on apoptosis. In addition, each compound reduced NF‑κB nuclear accumulation, with their combined treatment producing a deeper inhibition—consistent with their different modes of NF‑κB modulation.
Featured Image
Photo by Md Shakil Photography on Unsplash
Why is it important?
Carfilzomib is an effective therapy for multiple myeloma but can be limited by toxicity and resistance. Identifying agents that enhance its activity without overlapping mechanisms may help optimize treatment strategies. The results show that curcumin can amplify CFZ’s antiproliferative and proapoptotic actions while independently suppressing NF‑κB, a pathway relevant to myeloma survival and drug resistance. These findings contribute to the rationale for exploring supportive natural compounds that act on complementary signaling pathways, potentially improving therapeutic responses.
Perspectives
The data come from in vitro experiments on a single myeloma cell line; therefore, further studies—including co‑culture systems with bone marrow stromal cells, in vivo models, and mechanistic analyses—are needed to confirm the relevance of these interactions. Since stromal cells strongly modulate myeloma survival and drug resistance, extending this combination to microenvironment‑aware models would clarify whether curcumin can counteract stromal protection, as previously reported for bortezomib. Future work should also define dose‑response relationships, assess long‑term effects, and explore whether curcumin influences CFZ pharmacodynamics through additional redox‑ or inflammation‑related pathways.
Prof. Antonio Speciale
University of Messina
Read the Original
This page is a summary of: Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways, Toxicology in Vitro, March 2018, Elsevier,
DOI: 10.1016/j.tiv.2017.12.001.
You can read the full text:
Contributors
The following have contributed to this page
